Hillhouse Capital sold HK$2.08 billion worth of BeiGene (SHA:688235, HKG:6160) shares at HK$130 each as it cashed in on the surge of the latter's shares, YiCai Global reported Thursday.
The sale trimmed Hillhouse Capital's stake in the drug company to 4.89% from 6.03%, according to the report.
Hillhouse Capital also joined GIC and UBS as a cornerstone investor in Jiangsu Hengrui Pharmaceuticals' (SHA:600276, HKG:1276) upcoming 13.1 billion-yuan secondary listing on the Hong Kong bourse, YiCai Global wrote.
(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.